Daluzo is a innovative immunoglobulin, particularly designed as a humanized therapeutic protein targeting DLL3 conventional protein 3 (DLL3), who is a critical role in hematopoietic root lineage maturation and tumor vessel formation. The agent, also known as Dalotuzumab, presents compelling medicinal response in individuals diagnosed with aggressiv